Day One Biopharmaceuticals
Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.
Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications.
The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners.
You can read more here.
Please look for a planned CAC2 webinar later this year with representatives from Day One, OncoHeroes, and other companies devoting resources to developing drugs for children with cancer.
Categories
- Blog Posts (91)
- Explainer Post (11)
- Guest Blogs (15)
- Member Blogs (37)
- Survivorship Matters Blog (9)
- CAC2 News (25)
- Collaborative Achievements (13)
- Community News (233)
- In Memoriam (2)
- News Digest (186)
- Webinars (64)
Tags
Recent Posts
- CAC2 Childhood Cancer Community News Digest (July 15-21)
- CAC2 Collaborative Achievement–CAC2 Members Build Framework for Advancing Pediatric Cancer Research and Drug Development
- CAC2 Childhood Cancer Community News Digest (July 8-14)
- CAC2 Childhood Cancer Community News Digest (July 1-7)
- NCI Advocacy Update